Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction

Chinese PLA General Hospital (301 Hospital)

Status: Completed

Conditions: Coronary Angiography; Glucagon-like Peptide-1

Treatments: Diagnostic Test: plasma glucagon-like peptide-1 levels

Study type: Observational

Funder types: Other

Identifiers

NCT03129594

GLP1AMI

Details and patient eligibility

About

GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects. Direct administration of GLP-1(9-36) during reperfusion reduced ischaemic damage in isolated hearts and increased cGMP release, vasodilatation and coronary flow in AMI mouse model, one may speculate that total GLP-1 level may associate with adverse cardiovascular events in AMI patients, the hypothesis is therefore tested in this study.

Enrollment: 709 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• consecutive patients of acute AMI come to our department,absent of cardiogenic shock, and survival for at least 24 h after PCI treatment.

Exclusion criteria

• patients with cancer, and patients who were taking a DPP4 inhibitor or a glucagon-like peptide-1 (GLP-1) analogue